Integrating oncolytic viruses in combination cancer immunotherapy
/in International Publications, Newcastle Disease Virus /von 2018-08-01 / Nat. Rev. Immunol. 2018 Aug;18(8):498-513Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells
/in Immunogenic Cell Death, International Publications, Newcastle Disease Virus, NSCLC, SCLC /von 2018-08-01 / Am J Cancer Res 2018;8(8):1514-1527Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2018-07-31 / Sci Rep 2018 Jul;8(1):11470Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells
/in International Publications, Newcastle Disease Virus, Thyroid Cancer /von 2018-07-18 / BMC Cancer 2018 Jul;18(1):746Exploiting Viruses to Treat Diseases
/in International Publications, Newcastle Disease Virus /von 2018-06-26 / N. Engl. J. Med. 2018 07;379(2):194-196Recurrent Glioblastoma Treated with Recombinant Poliovirus
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2018-06-26 / N. Engl. J. Med. 2018 07;379(2):150-161Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2018-06-19 / Oncotarget 2018 Jun;9(47):28702-28716The effect of Newcastle disease virus on tumor proliferation and cellular immunity.
/in International Publications, Newcastle Disease Virus /von 2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e15174)Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2018-05-22 / Oncol Lett 2018 Jul;16(1):1180-1188
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution